H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on AzurRx BioPharma Inc (AZRX) today and set a price target of $8. The company’s shares closed yesterday at $2.01.
According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -12.3% and a 31.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on AzurRx BioPharma Inc is a Strong Buy with an average price target of $6.33, implying a 214.9% upside from current levels. In a report issued on February 14, Maxim Group also initiated coverage with a Buy rating on the stock with a $5 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.75 and a one-year low of $1. Currently, AzurRx BioPharma Inc has an average volume of 85.16K.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AZRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AzurRx BioPharma, Inc. is a development stage company, which engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. It offers MS1819 and AZX1101 that are therapeutic proteins products under development. The company was founded on January 30, 2014 and is headquartered in Brooklyn, NY.
